CONTROLLED RELEASE COMPLEX FORMULATION COMPRISING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND HMG-COA REDUCTASE INHIBITORS

摘要

A controlled release complex formulation comprising dihydropyridine calcium channel blockers and HMG(3-hydroxy-3-methylglutaryl)-CoA reductase inhibitors is provided to improve anti-hypertension effects in a synergism manner by releasing the drugs in a different time and inhibiting side effects caused by reacting them. A controlled release complex formulation comprises 1-20 mg of dihydropyridine calcium channel blockers in a controlled release partition and 5-160 mg of statin lipid lowering agents such as HMG-CoA reductase inhibitors in a rapid release partition, wherein the dihydropyridine calcium channel blockers and statin lipid lowering agents are related to an identical cytochrome P 450 enzyme and show antagonistic function when they are present in the liver simultaneously.